M. Blaskovich

发表

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

W. Guida, J. Turkson, R. Jove, 2007, Proceedings of the National Academy of Sciences.

A Phase I Clinical-Pharmacodynamic Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with the Proteasome Inhibitor Bortezomib in Advanced Acute Leukemias

C. Cubitt, Shumin M. Zhang, D. Sullivan, 2008, Clinical Cancer Research.

Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling.

Sheng Wei, S. Sebti, L. Moscinski, 2008, Blood.

Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells.

A. Vasudevan, S. Sebti, A. Hamilton, 1998, American journal of physiology. Lung cellular and molecular physiology.

Inhibition of Protein Geranylgeranylation Causes a Superinduction of Nitric-oxide Synthase-2 by Interleukin-1β in Vascular Smooth Muscle Cells*

S. Sebti, A. Hamilton, T. Mcguire, 1997, The Journal of Biological Chemistry.

A Non-peptide Mimetic of Ras-CAAX: Selective Inhibition of Farnesyltransferase and Ras Processing (*)

S. Sebti, A. Hamilton, Y. Qian, 1995, The Journal of Biological Chemistry.

Peptidomimetic inhibitors of p21ras farnesyltransferase: Hydrophobic functionalization leads to disruption of p21ras membrane association in whole cells

S. Sebti, A. Hamilton, Y. Qian, 1994 .

Farnesyltransferase and geranylgeranyltransferase I inhibitors upregulate RhoB expression by HDAC1 dissociation, HAT association and histone acetylation of the RhoB promoter

S. Sebti, S. Chellappan, A. Hamilton, 2007, Oncogene.

Design of GFB-111, a platelet-derived growth factor binding molecule with antiangiogenic and anticancer activity against human tumors in mice

D. Coppola, S. Sebti, A. Hamilton, 2000, Nature Biotechnology.

Tipifarnib-mediated suppression of T-bet-dependent signaling pathways

Sheng Wei, S. Sebti, J. Djeu, 2012, Cancer Immunology, Immunotherapy.

Requirement for geranylgeranyl transferase I and acyl transferase in the TGF-beta-stimulated pathway leading to elastin mRNA stabilization.

S. Sebti, A. Hamilton, U. Kucich, 1998, Biochemical and biophysical research communications.

Design, synthesis, and evaluation of potent and selective benzoyleneurea-based inhibitors of protein geranylgeranyltransferase-I.

S. Sebti, A. Hamilton, M. Blaskovich, 2005, Bioorganic & medicinal chemistry.

Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.

S. Sebti, A. Hamilton, Jiazhi Sun, 1999, Cancer research.

Blockade of Protein Geranylgeranylation Inhibits Cdk2-Dependent p27Kip1 Phosphorylation on Thr187 and Accumulates p27Kip1 in the Nucleus: Implications for Breast Cancer Therapy

S. Sebti, Aslamuzzaman Kazi, A. Hamilton, 2009, Molecular and Cellular Biology.

Prenyloxyphenylpropanoids as novel lead compounds for the selective inhibition of geranylgeranyl transferase I.

S. Sebti, A. Hamilton, S. Genovese, 2007, Bioorganic & Medicinal Chemistry Letters.

Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents.

William P. Katt, M. Gelb, L. Beese, 2010, Journal of medicinal chemistry.

Development of a tripeptide mimetic strategy for the inhibition of protein farnesyltransferase

S. Sebti, A. Hamilton, Y. Qian, 2000 .

Prenyltransferase inhibitors block superoxide production by pulmonary vascular smooth muscle.

S. Sebti, A. Hamilton, B. Pitt, 2000, American journal of physiology. Lung cellular and molecular physiology.

ALUNG February 22/2

S. Sebti, V. Kagan, M. Blaskovich, 2000 .

Desensitization of 5HT2 Receptors by Protein Kinase C Activation in Distal Pulmonary Vascular Smooth Muscle Cells in Culture

S. Sebti, B. Pitt, I. Reynolds, 1994, Microcirculation.

Cytotoxic Agents Cisplatin , Taxol , and Gemcitabine Geranylgeranyltransferase I : Combination Therapy with the Peptidomimetic Inhibitors of Farnesyltransferase and Antitumor Efficacy of a Novel Class of Non-thiol-containing Updated Version

S. Sebti, A. Hamilton, Jiazhi Sun, 1999 .

Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells.

A. Vasudevan, S. Sebti, A. Hamilton, 1998, The American journal of physiology.

Structure-based design of imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase.

S. Sebti, A. Hamilton, Jiazhi Sun, 2006, Organic & biomolecular chemistry.

Lysophosphatidic Acid Acyltransferase Beta Regulates mTOR Signaling

S. Sebti, H. Lawrence, M. Blaskovich, 2013, PLoS ONE.

Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.

J. Turkson, R. Jove, A. Cantor, 2003, Cancer research.

Design and synthesis of potent nonpeptidic farnesyltransferase inhibitors based on a terphenyl scaffold.

S. Sebti, A. Hamilton, Y. Qian, 2002, Journal of medicinal chemistry.

Synthesis and evaluation of potent, highly-selective, 3-aryl-piperazinone inhibitors of protein geranylgeranyltransferase-I.

S. Sebti, A. Hamilton, M. Blaskovich, 2006, Organic & biomolecular chemistry.

Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors

D. Coppola, S. Sebti, A. Hamilton, 2004, Oncogene.

Blocking Angiogenesis and Tumorigenesis with GFA-116, a Synthetic Molecule that Inhibits Binding of Vascular Endothelial Growth Factor to its Receptor

D. Coppola, S. Brem, S. Sebti, 2004, Cancer Research.

Structural basis for binding and selectivity of antimalarial and anticancer ethylenediamine inhibitors to protein farnesyltransferase.

Steven Fletcher, M. Gelb, L. Beese, 2009, Chemistry & biology.

Peptidomimetic inhibitors of protein farnesyltransferase show potent antimalarial activity.

S. Croft, M. Gelb, S. Sebti, 2001, Bioorganic & medicinal chemistry letters.

Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity

D. Coppola, R. Jove, S. Sebti, 2008, Oncogene.

Module assembly for protein-surface recognition: geranylgeranyltransferase I bivalent inhibitors for simultaneous targeting of interior and exterior protein surfaces.

S. Sebti, M. Blaskovich, N. Kato, 2008, Chemistry.

Inhibitors of protein farnesyltransferase as novel anticancer agents.

S. Sebti, A. Hamilton, M. Blaskovich, 2002, Current Topics in Medicinal Chemistry.

Activation of Dendritic Cells via Inhibition of Jak2/STAT3 Signaling1

Daniele M. Gilkes, S. Sebti, A. Beg, 2005, The Journal of Immunology.

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

G. Linette, F. Haluska, D. Niedzwiecki, 2012, Journal of Translational Medicine.

Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)

G. Linette, F. Haluska, D. Niedzwiecki, 2006, Journal of Translational Medicine.

Withacnistin inhibits recruitment of STAT3 and STAT5 to growth factor and cytokine receptors and induces regression of breast tumours

S. Sebti, M. Blaskovich, X. Zhang, 2014, British Journal of Cancer.

Phase I Trial of a Combination of the Multikinase Inhibitor Sorafenib and the Farnesyltransferase Inhibitor Tipifarnib in Advanced Malignancies

C. Ng, R. Kurzrock, A. Naing, 2009, Clinical Cancer Research.

Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity

D. Coppola, R. Jove, S. Sebti, 2005, Oncogene.

Ras CAAX Peptidomimetic FTI-277 Selectively Blocks Oncogenic Ras Signaling by Inducing Cytoplasmic Accumulation of Inactive Ras-Raf Complexes (*)

C. Der, S. Sebti, A. Hamilton, 1995, The Journal of Biological Chemistry.

Lovastatin inhibits the stimulation of mitogen-activated protein kinase by insulin in HIRcB fibroblasts.

S. Sebti, T. Mcguire, M. Blaskovich, 1996, Archives of biochemistry and biophysics.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

In vitro and in vivo antimalarial activity of peptidomimetic protein farnesyltransferase inhibitors with improved membrane permeability.

D. Chakrabarti, S. Croft, M. Gelb, 2004, Bioorganic & medicinal chemistry.

Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening.

Perry Haaland, P. Haaland, K. Bhalla, 2004, Journal of immunological methods.

Design and structural requirements of potent peptidomimetic inhibitors of p21ras farnesyltransferase.

S. Sebti, A. Hamilton, Y. Qian, 1994, The Journal of biological chemistry.

CAAX peptidomimetic FTI-244 decreases platelet-derived growth factor receptor tyrosine phosphorylation levels and inhibits stimulation of phosphatidylinositol 3-kinase but not mitogen-activated protein kinase.

S. Corey, A. Hamilton, T. Mcguire, 1995, Biochemical and biophysical research communications.

Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I.

A. Vasudevan, S. Sebti, A. Hamilton, 1999, Journal of medicinal chemistry.

Clinical improvement by farnesyltransferase inhibition in NK large granular lymphocyte leukemia associated with imbalanced NK receptor signaling.

Sheng Wei, S. Sebti, L. Moscinski, 2008, Blood.

Structure-based design and synthesis of potent, ethylenediamine-based, mammalian farnesyltransferase inhibitors as anticancer agents.

William P. Katt, M. Gelb, L. Beese, 2010, Journal of medicinal chemistry.

873P In vivo persistence of Iovance tumour-infiltrating lymphocytes LN-145 in cervical cancer patients

A. Jazaeri, V. Gontcharova, E. Masteller, 2020 .

Abstract LB-069: Persistence of cryopreserved tumor-infiltrating lymphocyte product lifileucel (LN-144) in C-144-01 study of advanced metastatic melanoma

V. Gontcharova, M. Blaskovich, M. Simpson-Abelson, 2019, Immunology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.